

## STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Jeffery H. Corban Interim Cabinet Secretary Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Cynthia E. Beane Commissioner

## Pharmaceutical and Therapeutics Committee January 25th, 2023

Location: Webex only
Time: Executive Session 2:30 PM - 3:30 PM
Time: Open Session 3:30 PM - 5:00 PM
Charleston, WV 25301
(304) 558-1700

## <u>AGENDA</u>

- I. Executive Session- 2:30PM-3:30PM
- II. Call to Order Call in information for the 3:30 PM Open Session is 615-647-0981 meeting code 633 527 354#
- III. Welcome and Introductions
- IV. Housekeeping Items/Updates
  - a. Approval of the October 26th, 2022 Minutes
  - b. PDL Compliance/Generic Percent Report Updates
- V. Public Comments (Agenda classes only) Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Brian Thompson (Brian.M.Thompson@wv.gov) and Doug Sorvig (Richard.D.Sorvig@wv.gov) no later than January 11<sup>th</sup>, 2023. Comments will be forwarded to committee members prior to the meeting for their review and consideration.

Representatives of drug manufacturers being presented at P&T can register to be on hand to answer any questions put forth by P&T committee members. Registrants must provide a name, email address, name of drug and company they are representing, and provide a completed <u>disclosure</u> form to the email address above no later than January 11<sup>th</sup>, 2023.

## VI. New Business

- a. New Drug Reviews
  - i. AnticonvulsantsZonisade (zonisamide)
  - ii. Antidepressants, Other Auvelity (buproprion/dextromethorphan HBr)
  - iii. Antipsoriatics, Topical Zoryve (roflumilast)
    - iv. BPH Treatments
      Entadfi (finasteride/tadalafil)
    - v. Calcium Channel Blockers levamlodipine maleate
    - vi. Immunomodulators, Atopic Dermatitis Sotyktu (deucravacitinib)
  - vii. Intranasal Rhinitis Agents
    Ryaltris (olopatadine HCI/mometasone)
  - viii. PAH Agents PDE5s Tadliq (tadalafil)
- b. Therapeutic Class Reviews
  - i. Acne Products, Topical-Retinoids
  - ii. Antipsoriatics, Topical
  - iii. Hypoglycemics, Insulin and Related Agents
- VII. Old Business
- VIII. Other Business -
- IX. Next Meeting April 26<sup>th</sup>, 2023, Virtual Meeting 2:00PM 5:00PM
- X. Adjournment